Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 5 | 4 |
| List of Tables | 7 | 1 |
| List of Figures | 8 | 1 |
| Downstream Processing in Biopharmaceuticals - Introduction | 9 | 1 |
| Downstream Processing in Biopharmaceuticals - Market Overview | 10 | 5 |
| Overview of Biopharmaceuticals | 10 | 1 |
| Cytokines | 10 | 1 |
| Enzymes | 10 | 1 |
| Hormones | 10 | 1 |
| Clotting Factors | 10 | 1 |
| Vaccines | 11 | 1 |
| Monoclonal Antibodies | 11 | 1 |
| Cell Therapies | 11 | 1 |
| Antisense Drugs | 11 | 1 |
| Peptide Therapeutics | 11 | 1 |
| Overview of Downstream Processing in Biopharmaceuticals | 12 | 1 |
| A Typical Downstream Processing Operation | 13 | 1 |
| Initial Clarification | 13 | 1 |
| Initial Capture | 13 | 1 |
| Intermediate Purification | 13 | 1 |
| Final Polishing | 14 | 1 |
| Major Check Points during Downstream Processing | 14 | 1 |
| Clear Project Goal | 14 | 1 |
| Checks for Process Robustness | 14 | 1 |
| Validated Down-scale | 14 | 1 |
| Virus Clearance | 14 | 1 |
| Virus Panel | 14 | 1 |
| Spiking Studies | 14 | 1 |
| Downstream Processing in Biopharmaceuticals - Role of Downstream Processing in the Biopharmaceutical Industry | 15 | 9 |
| Major Reagents, Reagent Suppliers and Reagents Market related to Downstream Process | 18 | 1 |
| Major Reagents | 18 | 1 |
| Protein Extraction Kit/Reagents | 18 | 1 |
| Filter Media | 18 | 1 |
| Protein A Media | 18 | 1 |
| Balanced Salt Solutions | 18 | 1 |
| Biological Buffers | 18 | 1 |
| Polyethylene Glycol | 18 | 1 |
| Glycyl-glycine | 18 | 1 |
| 5Resin / Agarose | 19 | 1 |
| Reagent Suppliers | 19 | 2 |
| Reagent Market | 21 | 1 |
| Major Equipment Suppliers | 22 | 2 |
| Downstream Processing in Biopharmaceuticals - Downstream Processing Market for CMOs | 24 | 4 |
| Global CMO Market Overview | 24 | 1 |
| CMO Biopharmaceuticals Market Characterization | 24 | 2 |
| CMO Market Size for Downstream Processing | 26 | 2 |
| Downstream Processing in Biopharmaceuticals - Challenges and Unmet Needs in Downstream Bioprocess | 28 | 3 |
| Challenges | 28 | 1 |
| Chromatographic Capture | 28 | 1 |
| Reducing the Purification Steps | 28 | 1 |
| Titer Increment/Capacity Bottleneck | 29 | 1 |
| Virus Clearances | 29 | 1 |
| Scaling Up | 29 | 1 |
| Unmet Needs | 29 | 1 |
| Unmet Medical Needs | 29 | 1 |
| Realistic Achievement of Economies of Scale | 29 | 1 |
| Technological Development of Disposables at Large Scale | 30 | 1 |
| Reagent Costs and their Effectiveness | 30 | 1 |
| Downstream Processing in Biopharmaceuticals - Emerging Technologies and their Implications | 31 | 3 |
| Single Use Technology/Disposable Technology | 32 | 1 |
| Advantages | 32 | 1 |
| Disadvantages | 32 | 1 |
| Multi-column Chromatography | 32 | 1 |
| Advantages | 32 | 1 |
| Disadvantages | 33 | 1 |
| Tangential Flow Filtration | 33 | 1 |
| Advantages | 33 | 1 |
| Disadvantages | 33 | 1 |
| Downstream Processing in Biopharmaceuticals - Industry Analysis | 34 | 5 |
| Key Drivers and Restraints | 34 | 1 |
| Key Drivers of Downstream Processing Market | 34 | 1 |
| Changing Focus towards Downstream Processing | 34 | 1 |
| Multicolumn Chromatography will Dominate the Market | 34 | 1 |
| Single-use Technologies will be Widely Used | 34 | 1 |
| Increasing Size of Contract Manufacturing Organizations in Emerging Market | 34 | 1 |
| Key Restraints of Downstream Processing Market | 35 | 1 |
| High Cost | 35 | 1 |
| Low Technical Expertise | 35 | 1 |
| Reduced Number of Purification Runs | 35 | 1 |
| Porter s Five Forces Model for Industry Analysis | 36 | 1 |
| Barriers to Entry | 36 | 1 |
| Determinants of Buyers Power | 37 | 1 |
| Determinant of Suppliers Power | 37 | 1 |
| Threat of Substitute Products | 37 | 1 |
| Rivalry among Existing Firms | 37 | 1 |
| Major Events and their Impact Analysis | 38 | 1 |
| Downstream Processing in Biopharmaceuticals - Competitive Landscape | 39 | 17 |
| Market Dynamics of Downstream Processing and Impact | 39 | 1 |
| Market Structure | 39 | 1 |
| Key Equipment Players | 40 | 1 |
| Pall Corporation | 40 | 1 |
| Business Overview | 40 | 1 |
| M&A Deals | 41 | 1 |
| Millipore | 42 | 1 |
| Business Overview | 42 | 1 |
| M&A Deals | 43 | 1 |
| Sartorius Stedim Biotech S.A. | 44 | 1 |
| Business Overview | 44 | 1 |
| M&A Deals | 45 | 1 |
| Key Reagent Players | 46 | 1 |
| Life Technologies | 46 | 1 |
| Business Overview | 46 | 1 |
| M&A Deals | 47 | 1 |
| Sigma Aldrich | 48 | 1 |
| Business Overview | 48 | 1 |
| M&A Deals | 49 | 1 |
| Key CMO Players | 50 | 1 |
| Lonza | 50 | 1 |
| Business Overview | 50 | 1 |
| M&A Deals | 51 | 1 |
| Boehringer Ingelheim | 52 | 1 |
| Business Overview | 52 | 1 |
| M&A Deals | 53 | 1 |
| Diosynth Biotechnology | 54 | 1 |
| Business Overview | 54 | 1 |
| M&A Deals | 55 | 1 |
| Downstream Processing in Biopharmaceuticals - Appendix | 56 | 4 |
| Market Definitions | 56 | 1 |
| Abbreviations | 56 | 1 |
| Bibliography | 57 | 1 |
| Research Methodology | 58 | 2 |
| Coverage | 58 | 1 |
| Secondary Research | 58 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 59 | 1 |